Labiotech.eu

News and Trends 17 Jun 2016

After its drop earlier this year, Genticel goes back up the slope

Genticel has announced that not one but two milestones have been achieved in the development of its products, which focus on immunotherapies for cancers caused by the human papillomavirus. Genticel is developing GTL001 (named ProCervix in Europe) to answer an unmet medical need – the eradication of the virus HPV 16 or 18 (high-risk types that […]

June 17, 2016 - 3 minutesmins - By Jerome Topsent

News and Trends 17 Jun 2016

Apogenix’s lead Candidate has more than one Trick up its Sleeve

Apogenix‘s lead candidate APG101, which has shown great results in a phase II study to treat Glioblastoma, has a new target in line. But this time, it’s not against cancer… Apogenix is a Germany-based company developing innovative immuno-oncology therapeutics for cancer and other malignant diseases. It was founded in 2005 and has raised over €90M […]

June 17, 2016 - 3 minutesmins - By Jerome Topsent

News and Trends 17 Jun 2016

Effective anti-infectives for medically unmet diseases? Ask Novabiotics

Toulouse was fun, but it’s time to go somewhere new! Fan of the Highlands, the landscapes that made the Harry Potter scenery much more exciting and the Loch Ness Monster? I’m just asking because this week we are going to Scotland! Aberdeen is our final destination, and we are visiting Novabiotics, our Biotech of the […]

June 17, 2016 - 2 minutesmins - By Joachim Eeckhout

allecra forbion delos antibiotic resistance

News and Trends 16 Jun 2016

Novel Antibiotic for Resistant Bacteria gets a €22M Push from Key Investors

Allecra Therapeutics has raised €22M in its Series B round from some key investors. The money will back the Phase II trials for a new broad-spectrum antibiotic for resistant bacteria. The development of antibiotic resistance in bacteria has been one of the key concerns of healthcare authorities for quite some time. The World Health Organisation estimates […]

June 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

indiebio eu 2016 synthetic biology accelerator

News and Trends 16 Jun 2016

Europe’s Leading SynBio Incubator has 13 new Biotechs ready to Hatch

IndieBio is an accelerator program for new ideas in Synthetic Biology. The participants of the most recent edition (Summer 2016) have been hard at work in Ireland since May 3rd – and now you can take a peek at what’s going on. The objective of IndieBio‘s program is to unlock the creative potential of students, researchers or […]

June 16, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 16 Jun 2016

This German Diagnostic company was sold for €50M to the World leading Molecular Diagnostic company

Sividon was a spin-off from Siemens, founded in July 2011 – and it was just sold to the American Myriad Genetics ($2.2Bn market cap) for €50M, even though the company raised only €5M over its lifetime. A clear success story that I discussed with Karlheinz Schmelig, partner of Sividon’s Lead investor Creathor Venture. Sividon worked in […]

June 16, 2016 - 2 minutesmins - By Philip Hemme

eva daignostics startup battle labiotech refresh biotech

News and Trends 15 Jun 2016

Eva Diagnostics: “We identified the pain points of the Blood testing market” #LBRefresh

Eva Diagnostics was one of the contestants at our Startup Battle during Labiotech Refresh. Take a second look with us at the pitch of Eva’s exciting diagnostic Tech… We had Sabine Dziemian, the head of data analysis at Eva Diagnostics, explain how this spin-off out of Imperial College London is joining the race for MedTech diagnostics. […]

June 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 15 Jun 2016

Boosting a Single Protein makes for a 50% more Productive Rice

Researchers from the John Innes Centre and Nanjing Agricultural University have identified a protein that can help plants regulate their cell pH – a seemingly small modification that can boost rice crop yields by 50%. Rice is one of the major crops in the world, along with corn and wheat (also under the microscope of science […]

June 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 15 Jun 2016

Dutch Fund raises €250M to invest in Late Stage Biotechs

Gilde Healthcare has raised €250M for its 4th fund in an oversubscribed round. The money will go to late-stage MedTech, digital health and therapeutics, which can join a portfolio with some of the European celebrity-Biotechs. Gilde Healthcare is based in Utrecht (Netherlands) and Cambridge (Massachussets), investing in healthcare companies on both sides of the Atlantic. This VC […]

June 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

diabetes glucose chronic disease biotech pharma review

News and Trends 14 Jun 2016

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Given the rates of diabetes reaching ‘epidemic proportions’, we figured it was time to have a better overview of biotech’s progress in the field. With some serious advances having been made in the treatment of the disease, we have to ask – how much further can biotech go in the treatment of diabetes? It is important […]

June 14, 2016 - 9 minutesmins - By Dani Bancroft

ziarco atopic dermatitis psoriasis skin inflammation

News and Trends 14 Jun 2016

British Biotech startup shows 50% improvement in Atopic Dermatitis

Ziarco has received positive results from a Phase II trial with its leading candidate, which has shown to improve symptoms of atopic dermatitis by 50%, giving it the potential to fill the current need for a safe oral treatment for this inflammatory skin disease. Ziarco is a private biotech with a clinical-stage pipeline for inflammatory skin […]

June 14, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 14 Jun 2016

Unlock the power of Text-mining tools

It has become clear that text mining is a great tool for rapid analysis of large volumes of biomedical literature. It delivers valuable information that helps to improve the accuracy and speed of the R&D process, as well as creating the opportunity to make more informed business decisions. As we’ve seen in our previous articles, text […]

June 14, 2016 - 4 minutesmins - By Jerome Topsent

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

After its drop earlier this year, Genticel goes back up the slope

Apogenix’s lead Candidate has more than one Trick up its Sleeve

Effective anti-infectives for medically unmet diseases? Ask Novabiotics

Novel Antibiotic for Resistant Bacteria gets a €22M Push from Key Investors

Europe’s Leading SynBio Incubator has 13 new Biotechs ready to Hatch

This German Diagnostic company was sold for €50M to the World leading Molecular Diagnostic company

Eva Diagnostics: “We identified the pain points of the Blood testing market” #LBRefresh

Boosting a Single Protein makes for a 50% more Productive Rice

Dutch Fund raises €250M to invest in Late Stage Biotechs

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

British Biotech startup shows 50% improvement in Atopic Dermatitis

Unlock the power of Text-mining tools

Subscribe to our newsletter to get the latest biotech news!